Tevogen (TVGN) Current Leases (2023 - 2026)
Tevogen's (TVGN) quarterly Current Leases came in at $327740.0 in Q1 2026, up 91.83% on a YoY basis from $170851.0 in Q1 2025, and little changed quarter-over-quarter from $327740.0 in Q4 2025.
Analysis
Tevogen (TVGN) Current Leases (2023 - 2026) Analysis & Trends
Tevogen (TVGN) has reported Current Leases for 4 consecutive years, with $327740.0 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Current Leases rose 91.83% year-over-year to $327740.0; the trailing twelve-month figure through Mar 2026 stood at $327740.0 (up 91.83% YoY), and the FY2025 full-year result was $327740.0, up 43.08% from the prior year.
- Current Leases steadied at $327740.0 in Q1 2026 per TVGN's latest filing, from $327740.0 in the prior quarter.
- Across five years, Current Leases topped out at $327740.0 in Q2 2025 and bottomed at $170851.0 in Q1 2025.
- Historically, Current Leases has averaged $275135.0 across 4 years, with a median of $264627.5 in 2024.
- The sharpest annual moves came in 2025 and 2026: Current Leases sank 34.44% in 2025, then surged 91.83% in 2026.
- Over 4 years, Current Leases stood at $252714.0 in 2023, then declined by 9.36% to $229063.0 in 2024, then jumped by 43.08% to $327740.0 in 2025, then changed by 0.0% to $327740.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $327740.0, $327740.0, and $327740.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 1.81 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 18.65 Mn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 2.67 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | - |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 2.99 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 15.21 Mn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 1.06 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 14.16 Mn |
| 10 | Tevogen | 27.76 Mn | 27.76 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 327,740.00 |
| Dec 31, 2025 | 327,740.00 |
| Sep 30, 2025 | 327,740.00 |
| Jun 30, 2025 | 327,740.00 |
| Mar 31, 2025 | 170,851.00 |
| Dec 31, 2024 | 229,063.00 |
| Sep 30, 2024 | 258,507.00 |
| Jun 30, 2024 | 268,672.00 |
| Mar 31, 2024 | 260,583.00 |
| Dec 31, 2023 | 252,714.00 |